The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | MASTER: Dara-KRd in patients with multiple myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses findings from the Phase II MASTER trial (NCT03224507), which investigated daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) followed by autologous transplantation in patients with newly diagnosed multiple myeloma (MM). Patients additionally received Dara-KRd consolidation based on minimal residual disease (MRD) status, with the primary endpoint being MRD negativity. A majority of the cohort achieved a complete response and MRD negativity, but progression-free survival was lower in patients with ultra-high risk MM. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
